The main advancement in cancer treatment over the past decade has been the introduction of T cell-targeted immunomodulators that block immune checkpoints CTLA-4 and PD1 or PDL1 that are expressed by tumor cells and permits them to avoid T cells’ antitumor activity. Here, CD274 is linked to neoplasm.